Core Viewpoint - He Yuan Bio (688765) reported significant revenue growth in 2025, driven by the successful market launch of its new product, Aofumin, and ongoing R&D efforts [1] Financial Performance - The company achieved an operating revenue of 47.8614 million yuan in 2025, representing a year-on-year increase of 89.8% [1] - The net profit attributable to shareholders was -158 million yuan [1] Product Development - The rapid sales breakthrough of Aofumin, which was approved for market launch in July 2025, contributed significantly to revenue growth [1] - Continuous market promotion and increasing recognition of the product's clinical value by end-users are key factors supporting the company's growth [1] Research and Development - The company maintains a high level of R&D investment to support the ongoing output of research results [1] - The steady progress of various stages in the R&D pipeline is crucial for the company's long-term development [1]
禾元生物2025年净利亏损1.58亿元